Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety and Efficacy of Daily Use of Micamlo® Combination Tablets AP in Patients With Hypertension

Completed

Conditions: Hypertension

Interventions: Drug: Micamlo

First Posted Date: 2011-05-13

Last Posted Date: 2014-08-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1157

Registration Number: NCT01353274

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site 37, Hitachiota, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 199, Akaiwa, Japan
🇯🇵
Boehringer Ingelheim Investigational Site 25, Akita, Japan

and more 251 locations

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: BI 137882
Drug: Placebo

First Posted Date: 2011-05-05

Last Posted Date: 2016-09-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT01348165

BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Volasertib, low dose, d1q3w
Drug: Volasertib, middle dose, d1q3w
Drug: Volasertib, high dose, d1q3w

First Posted Date: 2011-05-05

Last Posted Date: 2018-08-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT01348347

Locations: 🇯🇵
1230.15.001 National Cancer Center Hospital,, Chuo-ku, Tokyo, Japan

Single Rising Dose Study of BI 207127 NA in Healthy Male Asian Volunteers and Single Dose Study of BI 207127 NA in Healthy Male Caucasian Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 207127 NA (low dose)
Drug: Matching placebo (low dose)
Drug: BI 207127 NA (medium dose)
Drug: Matching placebo (medium dose)
Drug: BI 207127 NA (high dose)
Drug: Matching placebo (high dose)

First Posted Date: 2011-05-04

Last Posted Date: 2016-04-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01347086

Locations: 🇰🇷
1241.8.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of

A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BIBF 1120
Drug: Placebo

First Posted Date: 2011-05-03

Last Posted Date: 2018-09-10

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT01346540

Locations: 🇳🇱
1199.82.3102 Boehringer Ingelheim Investigational Site, Maastricht, Netherlands
🇪🇸
1199.82.3406 Boehringer Ingelheim Investigational Site, Madrid, Spain
🇪🇸
1199.82.3410 Boehringer Ingelheim Investigational Site, Málaga, Spain

and more 4 locations

LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Phase 3

Completed

Conditions: Head and Neck Neoplasms
Carcinoma, Squamous Cell

Interventions: Drug: Methotrexate
Drug: Afatinib

First Posted Date: 2011-05-02

Last Posted Date: 2018-02-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 483

Registration Number: NCT01345682

Locations: 🇯🇵
1200.43.08111 Boehringer Ingelheim Investigational Site, Hyogo, Akashi, Japan
🇯🇵
1200.43.08107 Boehringer Ingelheim Investigational Site, Hyogo, Kobe, Japan
🇫🇷
1200.43.03303 Boehringer Ingelheim Investigational Site, Lille Cedex, France

and more 98 locations

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Phase 3

Terminated

Conditions: Head and Neck Neoplasms

Interventions: Drug: Afatinib
Drug: Placebo

First Posted Date: 2011-05-02

Last Posted Date: 2017-12-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 617

Registration Number: NCT01345669

Locations: 🇧🇷
1200.131.05555 Boehringer Ingelheim Investigational Site, Jau, Brazil
🇦🇺
1200.131.06151 Boehringer Ingelheim Investigational Site, Wooloongabba, Queensland, Australia
🇦🇷
1200.131.05451 Boehringer Ingelheim Investigational Site, Ciudad Autonoma de Bs As, Argentina

and more 159 locations

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Telmisartan/Amlodipin FDC
Drug: Telmisartan
Drug: Amlodipin

First Posted Date: 2011-04-29

Last Posted Date: 2014-03-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT01344629

Locations: 🇯🇵
1235.28.001 Boehringer Ingelheim Investigational Site, Kumamoto, Kumamoto, Japan

Single Rising Dose Study to Assess Safety, Tolerability and Pharmacokinetics of BI 661051.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 661051
Drug: Placebo

First Posted Date: 2011-04-28

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 64

Registration Number: NCT01343719

Locations: 🇩🇪
1296.1.1 Boehringer Ingelheim Investigational Site, Mannheim, Germany

Safety Tolerability and Pharmacokinetic of BI 409306

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 409306
Drug: Placebo

First Posted Date: 2011-04-28

Last Posted Date: 2024-04-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT01343706

Locations: 🇩🇪
1289.1.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy